Oncology Phase 3 Deal Benchmarks — US Only (2026)

Median upfront of $397M with total deal values reaching $2.2B in US Only territory.

Median Upfront

$397M

Total Deal Value

$1.7B

Royalty Range

13.4%–20.6%

Territory Multiplier

0.55x

Understanding Oncology Deal Benchmarks at Phase 3

Phase 3 Oncology licensing deals in US Only territory command a median upfront payment of $397M, with values ranging from $260M at the low end to $511M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the oncology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $1.3B to $2.2B, with a median of $1.7B. Royalty rates for oncology assets at this stage typically fall between 13.4% and 20.6% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The US Only territory applies a 0.55x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating us only rights should calibrate upfront expectations and milestone structures accordingly.

PRO

Full Market Analysis

Detailed deal economics, territory impact analysis, and royalty structure breakdown.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Full Benchmark Data

PRO

Full Benchmark Table

Low, median, and high ranges for upfront payments, total deal values, and royalty rates.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Comparable Deals

PRO

See All Comparable Deals

View 0 comparable Oncology transactions with upfront payments, total values, and deal structures.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Frequently Asked Questions

What is the average upfront payment for Phase 3 Oncology deals in US Only territory?

The median upfront payment for Phase 3 Oncology licensing deals in US Only territory is $397M, based on our analysis of comparable transactions. Values range from $260M for early-stage or less differentiated assets up to $511M for premium programs with strong clinical data or first-in-class mechanisms.

How does US Only territory affect Oncology deal value?

US Only rights carry a 0.55x multiplier relative to base deal economics. This means us only oncology deals are valued at a discount compared to single-country rights, reflecting the combined market opportunity, regulatory pathway, and competitive dynamics of the territory.

What royalty rates are typical for Phase 3 Oncology licensing?

Royalty rates for Phase 3 oncology assets typically range from 13.4% to 20.6% of net sales. The exact rate depends on the licensor's contribution (IP, clinical data, manufacturing), deal structure (exclusive vs. co-exclusive), and the licensee's commercialization investment. Higher royalties often correspond to lower upfront payments, and vice versa.

PRO

More Expert Insights

Territory impact analysis, royalty negotiation strategies, and deal structure guidance.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

$18M upfront

Oncology · Preclinical · US Only

$49M upfront

Oncology · Phase 1 · US Only

$142M upfront

Oncology · Phase 2 · US Only

$1.1B upfront

Oncology · Approved · US Only

$283M upfront

Neurology/CNS · Phase 3 · US Only

$495M upfront

Immunology · Phase 3 · US Only

$678M upfront

Metabolic/Obesity · Phase 3 · US Only

$721M upfront

Oncology · Phase 3 · Global

Explore More

All Oncology Deals

View full therapeutic area benchmarks

Licensing Benchmarks Guide

2026 data from 1,900+ deals

Royalty Rate Benchmarks

Negotiation strategies by phase & modality

Run Custom Analysis

Pre-filled with Oncology · Phase 3

Run Your Own Benchmark

These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.

Open Deal Calculator

Cite This Data

APA

Ambrosia Ventures. (2026). Oncology Phase 3 Deal Benchmarks — US Only (2026). Retrieved from https://calculator.ambrosiaventures.co/data/oncology-phase-3-deals-us

HTML

<a href="https://calculator.ambrosiaventures.co/data/oncology-phase-3-deals-us">Oncology Phase 3 Deal Benchmarks — US Only (2026)</a> — Ambrosia Ventures (2026)

Embed Chart

Data sourced from 1,900+ verified biopharma transactions. Updated monthly.

Metric	Low	Median	High
Upfront Payment	$260M	$397M	$511M
Total Deal Value	$1.3B	$1.7B	$2.2B
Royalty Rate	13.4%	—	20.6%